<p>Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives</p>

Abstract

Ankylosing spondylitis (AS) is a chronic rheumatic disease involving inflammation of the joints and spine, which carries a substantial, lifelong burden for the patient. Secukinumab is a fully human anti-interleukin-17A monoclonal antibody, approved in the USA and EU for the treatment of AS. In this narrative review, we searched PubMed with the aim of consolidating the recent literature regarding the impact of secukinumab on patientreported outcomes in patients with AS. A large clinical trial program has demonstrated the efficacy of secukinumab in relieving the signs and symptoms of AS. Most importantly from a patient perspective, secukinumab has produced improvements in a range of patient-reported outcomes (PROs), including pain, fatigue, quality of life and work productivity, as well as composite measures including patient-reported elements, such as the Bath indices and Assessment of SpondyloArthritis international Society (ASAS) response criteria. Benefits to patients were rapid, and sustained in the long term (up to 5 years). The positive effect of secukinumab was seen regardless of whether patients had previously been treated with antitumor necrosis factor (TNF) therapies. Greater improvements in PROs were associated with patients being anti-TNF-naïve, of a younger age, with shorter disease duration and higher objective measures of inflammation at baseline. The available real-world evidence suggests that the effects of secukinumab on PROs in clinical practice are consistent with those seen in clinical trials, and evidence in a real-world setting continues to be collected.

Short-term Efficacy and Safety of Secukinumab in Pakistani Patients with Ankylosing Spondylitis and Psoriatic Arthritis

“…The initial four components are measured on 0-10 cm VAS (Visual analogue score). 12 ASDAS cut-offs for disease activity are <1.3 for remission, <2.1 for low disease activity, ≤3.5 for high disease activity and >3.5 for very high disease activity. 11 BASDAI is a measure of disease activity for ankylosing spondylitis.…”

Fatigue in Inflammatory Joint Diseases

“…The chronic inflammation associated with AS, as well as the pain and stiffness in the spine and joints, can contribute to increased fatigue levels. Additionally, the immune system activation and the presence of depression or sleep disturbances can further exacerbate fatigue in AS [79]. The level of fatigue is one of the components used to assess disease activity in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), which is one of the most commonly used scales in patients with AS.…”

Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms

“…In these studies, patients answer surveys that address their pain, fatigue, mood/mental health, general health, sleep, and impact on activities of daily living. Post hoc analysis of secukinumab randomized clinical trials showed that secukinumab improved mental and physical health, as well as their perceived quality of life [ 80 •, 81 – 83 ]. In addition to their improved quality of life, these patients reported less work absenteeism and increased work productivity [ 81 ].…”